TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Actinogen Medical ( (AU:ACW) ) has shared an update.
Actinogen Medical Limited has announced the quotation of 1,078,721 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of December 1, 2025. This move is part of the company’s strategic efforts to enhance its capital structure and support ongoing research and development activities, potentially strengthening its position in the biotechnology sector.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
More about Actinogen Medical
Actinogen Medical Limited operates in the biotechnology industry, focusing on the development of innovative therapies for neurological and neurodegenerative diseases. The company is primarily engaged in advancing its lead compound, Xanamem, which targets cognitive impairment associated with chronic neurological conditions.
YTD Price Performance: 140.0%
Average Trading Volume: 3,961,444
Technical Sentiment Signal: Buy
Current Market Cap: A$190.9M
See more insights into ACW stock on TipRanks’ Stock Analysis page.